Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06444984
Other study ID # 2141491-1
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 24, 2024
Est. completion date March 2025

Study information

Verified date May 2024
Source Ball State University
Contact Bryant Keirns, PhD
Phone 7652858356
Email bryant.keirns@bsu.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Increasing attention has been paid to meals with unusual characteristics that are consumed on a semi-regular basis (e.g., "tailgating," pizza buffets). The purpose of this study is to describe the acute cardiometabolic effects of a cinema-style meal rich in refined sugar, total carbohydrate, and moderate in fat (i.e., soda, popcorn, candy).


Description:

Participants will complete two study visits in random order. For one visit, participants will consume popcorn (6 cups popped microwave popcorn), soda (32 oz Coke-a-cola), and candy (2.17 oz of Skittles) in the morning while fasting (i.e., the "fasting trial"). For the other visit, participants will report fasting and then first consume a high-fat meal (two Jimmy Dean's breakfast sandwiches; the "fed trial"). After consuming the high-fat meal during the fed trial, participants will be allowed to leave for three hours. During this three-hour period, the investigators will ask participants to only consume water and remain sedentary. Upon return, participants will consume the same movie theater style meal (popcorn, soda, candy). Regardless of fasting or fed trials, procedures for this study will be largely similar between the two visits. Participants will arrive having fasted for ~10 hours, avoided exercise and alcohol for > 24 hours, and avoided anti-inflammatory medications for > 72 hours. First, the investigators will perform a baseline vascular ultrasound using the flow-mediated dilation (FMD) technique on all participants. Upon completion of FMD, the investigators will perform a blood draw in one of two ways (depending on the trial). For the fasting trial, the investigators will insert an indwelling intravenous catheter (IV) to minimize needle sticks. After a baseline blood sample is collected, participants will consume the movie theater-style meal and remain in the lab for four hours. During this time, the investigators will collect blood samples at 0.5-, 1-, 2-, 3-, and 4-hours post meal to measure potential changes in metabolic and inflammatory markers and indicators of endotoxemia. The investigators will also measure FMD at 2- and 4-hours post movie theater-style meal. During the fed trial, the investigators will first perform a single venipuncture to obtain a blood sample in order to have a true baseline sample for the fed trial. When participants return from this three-hour break, the procedures for the fed trial will be identical to the fasting trial (IV inserted, moving theater meal consumed, serial blood draws and FMD completed at the same timepoints over a four-hour period).


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date March 2025
Est. primary completion date September 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - 18-45 years old - Not pregnant or expecting to become pregnant (females only) - Not postmenopausal (females only). - Not been diagnosed with a cardiometabolic conditions (e.g., heart disease, type 2 diabetes) - Not been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease). - Does not regularly take anti-inflammatory drugs (more than 2x week) or able to temporarily suspend use of anti-inflammatory drugs. - Does not use glucose-lowering drugs (e.g., metformin) - Does not use lipid-lowering drugs (e.g., statins) - Does not use tobacco products or any illicit drugs. - Does not have a pacemaker. Exclusion Criteria: - Not 18-45 years old - Pregnant or expecting to become pregnant (females only) - Postmenopausal (females only). - Been diagnosed with a cardiometabolic conditions (e.g., heart disease, type 2 diabetes) - Been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease). - Regularly take anti-inflammatory drugs (more than 2x week) or unable to temporarily suspend use of anti-inflammatory drugs. - Use glucose-lowering drugs (e.g., metformin) - Use lipid-lowering drugs (e.g., statins) - Use tobacco products or any illicit drugs. - Has a pacemaker.

Study Design


Intervention

Other:
Fasting Trial
Participants will report fasted and consume popcorn (6 cups popped microwave popcorn), soda (32 oz Coke-a-cola), and candy (2.17 oz of Skittles) in the morning.
Fed Trial
Participants will report fasted and first consume a high-fat meal (Jimmy Deans) in the morning. After a three-hour break, participants will consume popcorn (6 cups popped microwave popcorn), soda (32 oz Coke-a-cola), and candy (2.17 oz of Skittles).

Locations

Country Name City State
United States Health Professions Building, Ball State University Muncie Indiana

Sponsors (1)

Lead Sponsor Collaborator
Ball State University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Glucose The investigators will measure glucose at baseline and 0.5-, 1-, 2-, 3-, and 4-hours after each meal trial. Through study completion, up to 1 year.
Primary Insulin The investigators will measure serum insulin at baseline and 0.5-, 1-, 2-, 3-, and 4-hours after each meal trial. Through study completion, up to 1 year.
Primary Triglycerides The investigators will measure triglycerides at baseline and 0.5-, 1-, 2-, 3-, and 4-hours after each meal trial. Through study completion, up to 1 year.
Primary HDL-C The investigators will measure HDL-C at baseline and 0.5-, 1-, 2-, 3-, and 4-hours after each meal trial. Through study completion, up to 1 year.
Primary Lipopolysaccharide binding protein (LBP) The investigators will measure serum LBP at baseline and 0.5-, 1-, 2-, 3-, and 4-hours. after each meal trial. Through study completion, up to 1 year.
Primary soluble CD14 (sCD14) The investigators will measure serum sCD14 at baseline and 0.5-, 1-, 2-, 3-, and 4-hours after each meal trial. Through study completion, up to 1 year.
Primary Interleukin (IL)-6 The investigators will measure serum IL-6 at baseline and 0.5-, 1-, 2-, 3-, and 4-hours after each meal trial. Through study completion, up to 1 year.
Primary Flow-mediated dilation The investigators will measure FMD at baseline, 2-hours, and 4-hours after each meal trial. Through study completion, up to 1 year.
See also
  Status Clinical Trial Phase
Completed NCT05733455 - Effect of Alpelisib in Healthy Volunteers Phase 1
Recruiting NCT05126199 - Time-restricted Eating to Improve Metabolic Abnormalities in Polycystic Ovarian Syndrome N/A
Completed NCT00409422 - Effects of a Comprehensive Weight Management Program on Obese Adolescents and Children N/A
Completed NCT00005760 - Health Effects of Liposuction in Overweight Women With Elevated Insulin Levels, Impaired Glucose Tolerance and/or Type 2 Diabetes N/A
Completed NCT00005669 - Metformin to Treat Obesity in Children With Insulin Resistance Phase 2
Completed NCT01409382 - Maternal Lifestyle and Neonatal Hypoglycemia N/A
Completed NCT00667498 - Metabolic Effect of Metformin in Obese Insulin Resistant Adolescents With Normal Glucose Tolerance Phase 4
Completed NCT00001624 - Effect of Insulin on Endothelin-Dependent Vascular Tone in the Forearm Circulation Phase 1
Completed NCT02653092 - Reprometabolic Syndrome Mediates Subfertility in Obesity N/A
Recruiting NCT05854251 - Hyperinsulinemia in Prediabetes Mediated by Interleukin-1β Phase 2
Completed NCT02852759 - A Cold Physical Treatment to Manage Insulin Resistance N/A
Recruiting NCT04309071 - Saliva Insulin Responses to a Standardized Meal Tolerance Test in Humans N/A
Completed NCT00618072 - EMPOWIR:Enhance the Metabolic Profile of Women With Insulin Resistance Phase 2
Completed NCT01125150 - Spectroscopic and Colorimetric Analysis of Acanthosis Nigricans in Patients With Hyperinsulinemia N/A
Suspended NCT03374215 - Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks
Recruiting NCT05724134 - Pancreatic Clamp in NAFLD Phase 1
Active, not recruiting NCT05135234 - Developing a Physiological Understanding of High Duration Activity N/A
Recruiting NCT05729282 - Glycemic Effect of Diazoxide in NAFLD Phase 1
Completed NCT00015691 - Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities N/A
Withdrawn NCT02642523 - Natriuretic Peptides and Metabolic Risk in Obesity Early Phase 1